Johnson & Johnson Operating Income 2006-2019 | JNJ

Johnson & Johnson annual/quarterly operating income history and growth rate from 2006 to 2019. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Johnson & Johnson operating income for the quarter ending September 30, 2019 was $1.647B, a 62.76% decline year-over-year.
  • Johnson & Johnson operating income for the twelve months ending September 30, 2019 was $16.232B, a 6.91% decline year-over-year.
  • Johnson & Johnson annual operating income for 2018 was $17.999B, a 1.84% increase from 2017.
  • Johnson & Johnson annual operating income for 2017 was $17.673B, a 10.76% decline from 2016.
  • Johnson & Johnson annual operating income for 2016 was $19.803B, a 3.16% increase from 2015.
Johnson & Johnson Annual Operating Income
(Millions of US $)
2018 $17,999
2017 $17,673
2016 $19,803
2015 $19,196
2014 $20,563
2013 $15,471
2012 $13,775
2011 $12,361
2010 $16,947
2009 $15,755
2008 $16,929
2007 $13,283
2006 $14,587
2005 $13,116
Johnson & Johnson Quarterly Operating Income
(Millions of US $)
Q3 2019 $1,647
Q2 2019 $7,041
Q1 2019 $4,422
Q4 2018 $3,122
Q3 2018 $4,423
Q2 2018 $4,973
Q1 2018 $5,481
Q4 2017 $2,560
Q3 2017 $4,790
Q2 2017 $4,748
Q1 2017 $5,575
Q4 2016 $4,324
Q3 2016 $5,281
Q2 2016 $4,904
Q1 2016 $5,294
Q4 2015 $3,758
Q3 2015 $4,122
Q2 2015 $5,741
Q1 2015 $5,575
Q4 2014 $2,703
Q3 2014 $6,810
Q2 2014 $5,626
Q1 2014 $5,424
Q4 2013 $2,750
Q3 2013 $3,667
Q2 2013 $4,793
Q1 2013 $4,261
Q4 2012 $3,100
Q3 2012 $3,595
Q2 2012 $2,035
Q1 2012 $5,045
Q4 2011 $318
Q3 2011 $4,111
Q2 2011 $3,422
Q1 2011 $4,510
Q4 2010 $2,228
Q3 2010 $4,219
Q2 2010 $4,220
Q1 2010 $6,280
Q4 2009 $2,604
Q3 2009 $4,245
Q2 2009 $4,263
Q1 2009 $4,643
Q4 2008 $3,517
Q3 2008 $4,290
Q2 2008 $4,375
Q1 2008 $4,747
Q4 2007 $2,332
Q3 2007 $3,268
Q2 2007 $4,031
Q1 2007 $3,652
Q4 2006 $2,708
Q3 2006 $3,661
Q2 2006 $3,603
Q1 2006 $4,615
Q4 2005 $2,503
Q3 2005 $3,420
Q2 2005 $3,266
Q1 2005 $3,927
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $366.830B $81.581B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Roche Holding AG (RHHBY) Switzerland $263.804B 0.00
Merck (MRK) United States $225.752B 17.49
Pfizer (PFE) United States $211.071B 12.55
Novartis AG (NVS) Switzerland $209.837B 17.71
Novo Nordisk (NVO) Denmark $135.852B 23.42
AbbVie (ABBV) United States $128.953B 10.10
AstraZeneca (AZN) United Kingdom $126.465B 22.84
Sanofi (SNY) France $116.718B 14.34
Eli Lilly (LLY) United States $113.939B 21.04
GlaxoSmithKline (GSK) United Kingdom $112.414B 13.62
Bristol-Myers Squibb (BMY) United States $95.965B 13.42
Bayer (BAYRY) Germany $71.769B 10.63
H Lundbeck (HLUYY) Denmark $7.657B 11.05